Assessment of drug-induced liver injury via nR modified Hy’s law and PALT

doi:10.19803/j.1672-8629.20230615

Abstract

Abstract: Hepatotoxicity associated with drugs, herbal medications and other complementary or alternative therapies has been a global concern for safety professionals and regulatory authorities. Instant identification of liver injury remains a challenge during both clinical development and in the post-marketing period. Advances have been made in the criteria used to identify cases of hepatotoxicity that are most likely to progress to liver failure or death. In addition, new methods are available to estimate the magnitude of hepatocyte loss associated with liver injury. This paper reviews these new methodologies and their applications to the ongoing monitoring and evaluation of product-related hepatoxicity.

Key words: drug-induced liver injury(DILI), herbal medications, complementary therapies, alternative therapies, Hy’s Law, eDISH, R value, nR value, P_ALT

CLC Number:

R969
R994.11

BUCHANAN James. Assessment of drug-induced liver injury via nR modified Hy’s law and P_ALT[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230615

https://www.zgywjj.com/EN/Y2024/V21/I1/117

References

[1] FDA. FDA Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation[EB/OL].[2023-09-12]. https://www.fda.gov/media/
116737/download.
[2] HILLMAN L, GOTTGRIED M, WHITSETT M, et al.Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J]. American Journal of Gastroenterology, 2016, 111(7): 958-965.
[3] WAI CT, TAN BH, CHAN CL, et al.Drug-induced liver injury at an Asian center: a prospective study[J]. Liver International, 2007, 27(40): 465-474.
[4] SHEN T, LIU Y, SHANG J, et al.Incidence and etiology of drug-induced liver injury in China[J]. Gastroenterology, 2019, 156(8): 2230-2241.
[5] MOSEDALE M, WATKINS P.Drug-induced liver injury: advances in mechanistic understanding that will inform risk management[J]. Clinical Pharmacology and Therapeutics, 2017, 101(4): 469-480.
[6] GARCIA-CORTES M, ROBLES-DIAZ M, STEPHENS C, et al.Drug induced liver injury: an update[J]. Archives of Toxicology, 2020, 94: 3381-3407.
[7] ZIMMERMAN HJ.Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver[M]. New York: Appleton-Century-Crofts, 1978.
[8] BJORNSSON E, OLSSON R.Outcome and prognostic markers in severe drug-induced liver disease[J]. Hepatology, 2005, 42(2): 481-489.
[9] ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al.Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521.
[10] SENIOR JR.Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges[J]. Drug Safety, 2014, 37(Suppl 1): S9-S17.
[11] American Statistical Association’s Biopharmaceutical Working Group. Interactive Safety Graphics[EB/OL].[2023-12-04]. https://safetygraphics.github.io/.
[12] BENICHOU C.Criteria of drug-induced liver disorders: report of an international consensus meeting[J]. Journal of Hepatology, 1990, 11: 272-276.
[13] AITHAL GP, WATKINS PB, ANDRADE RJ, et al.Case definition and phenotype standardization in drug-induced liver injury[J]. Clinical Pharmacology and Therapeutics, 2011, 89(6): 806-815.
[14] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. American Journal of Gastroenterology, 2014, 109: 950-966.
[15] ROBLES-DIAZ M, LUCENA MI, KAPLOWITZ N, et al.Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury[J]. Gastroenterology, 2014, 147(1): 109-118.
[16] MOLLER HJ, GRONBAEK H, SCHIODT FV, et al.Soluble CD163 from activated macrophages predicts mortality in acute liver failure[J]. Journal of Hepatology, 2007, 47(5): 671-676.
[17] HAYASHI PH, ROCKEY DC, FONTANA RJ, et al.Death and liver transplantation within 2 years of onset of drug-induced liver injury[J]. Hepatology, 2017, 66(4): 1275-1285.
[18] Interactive Safety Working Group Taskforce. Safety Graphics[EB/OL].[2023-12-04]. https://github.com/SafetyGraphics/hep-explorer.
[19] MERZ M, LEE KR, KULLAK-UBLICK GA, et al.Methodology to assess clinical liver safety data[J]. Drug Safety, 2014, 37(Suppl 1): S33-S45.
[20] Simulations-Plus.DILI-sim Initiative[EB/OL].[2023-12-04].https://www.simulations-plus.com/dilisym-services/dili-sim-initiative/.
[21] CHUNG JY, LONGO DM, WATKINS PB.A rapid method to estimate hepatocyte loss due to drug-induced liver injury[J]. Clinical Pharmacology and Therapeutics, 2019, 105(3): 746-753.

Assessment of drug-induced liver injury via nR modified Hy’s law and P_ALT

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

[1]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[2]	LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai. Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
[3]	ZHANG Xialan, SHEN Xikun, Huang Yuyu. Clinical Analysis of 130 Cases of Drug-induced Liver Injury in Cancer Patients [J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 589-593.
[4]	JIA Wang-ping, GUO Dai-hong, TIAN Xiao-yan, KOU Wei, WANG Xiao-yu, ZHAO Su-yu, HU Peng-zhou. Analysis of 1110 Cases of Drug-induced Liver Injury in 79 Hospitals [J]. Chinese Journal of Pharmacovigilance, 2017, 14(8): 481-485.